PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-89.95%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-95.43%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-134.36%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-134.21%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-134.21%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.82%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-141.82%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.42%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-31.42%
Negative 5Y OCF/share CAGR while Healthcare median is 12.77%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-183.28%
Negative 3Y OCF/share CAGR while Healthcare median is 5.49%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
1.36%
Below 50% of Healthcare median. Jim Chanos would suspect deeper issues limiting long-term profit growth.
1.36%
Below 50% of Healthcare median. Jim Chanos would suspect deeper problems limiting mid-term profit potential.
-52.35%
Negative 3Y CAGR while Healthcare median is 26.71%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-201.38%
Negative 3Y equity/share growth while Healthcare median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-99.57%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-12.67%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-28.84%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
60.35%
SG&A growth of 60.35% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.